Skip to main content

Openings for Life Sciences, Biochemistry, Microbiology, Biotechnology at RGCB

First Class Post-Graduate MSc Degree in Life Sciences (Microbiology/ Biotechnology/ Biochemistry etc). Hands on experience in plant tissue culture. Proficiency in Western blotting, PCR and microbial culture. 
Advertisement for JRF in CSIR Funded Project at IIT - B.Pharm, MSc Apply
B.S. 4 years programme, BPharm, Integrated BS-MS, MSc, BE, BTech or equivalent degree in Chemistry, Chemical Sciences, with 55% marks and passing of NET, GATE test with valid score card.
Malabar Cancer Centre Hiring Assistant Pharmacist
D.Pharm / B.Pharm, Experienced candidates in hospital sector will get preference. 
Indian Institute of Technology looking for PG in biotechnology or life sciences candidates
Postgraduate Degree in Basic Science or in Professional Course in biotechnology or life sciences related areas, with qualified CSIR UGC NET or GATE.
Applications are invited for SRF at University of Hyderabad
First class in M.Sc in Biochemistry, Biotechnology with >55% marks minimum of two years research experience in reputed national laboratories
Applications are invited for Project Associate at NIIST
M.Sc in Chemistry / Applied Chemistry / Organic Chemistry / Polymer Chemistry / Materials Science or equivalent from recognized University or Equivalent and 3 years of experience in R&D in Industrial and Academic Institutions.
Openings in Production Department at Macleods - B.Pharm, BSc Apply
Years of experience in Granulation/ Compression/ Coating/ Capsule Filling/ Liquid Manufacturing/ Packaging
Openings for B.Pharm, MSc in Production, QC, Store at Aarti Pharmalabs Limited
Hands-on experience in batch operations, GMP documentation, shift handling, and operation of equipment like reactors, centrifuges, and dryers.
Anixa Biosciences secures New U.S. Patent extending CAR-T Cancer Therapy Protection to 2045
Anixa Biosciences, Inc., a clinical-stage biotechnology company specializing in cancer treatment and prevention, has announced the issuance of a new U.S. patent for its chimeric antigen receptor-T cell (CAR-T) technology.
Zydus Lifesciences delivers steady growth in Q1 FY26, boosted by global expansion

Zydus Lifesciences Limited reported a steady performance for the quarter ended June 30, 2025, with growth across key geographies and strong contributions from innovation-driven initiatives. The pharmaceutical major posted revenue from operations of Rs. 65,737 million, marking a 6% increase year-on-year and a marginal 0.7% rise from the previous quarter. Net profit stood at Rs. 14,668 million, up 3% from the same quarter last year and a robust 25.3% higher than Q4 FY25.